Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

R. Coleman Lindsley, MD PhD, Christopher J. Gibson, MD, H. Moses Murdock, BS, Richard M. Stone, MD, Jorge E. Cortes, MD, Geoffrey L. Uy, MD, Tara L. Lin, MD, Ellen K. Ritchie, MD, Thomas Prebet, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 15.

https://doi.org/10.1182/blood-2019-124500

Published: 2019

Journal Articles

Correcting Rare Blood Disorders Using Coagulation Factors Produced In Vivo By Shielded Living Therapeutics TM Products

Guillaume Carmona, PhD, Lauren Barney, PhD, Jared Sewell, PhD, Ryan Newman, Christine Carroll, Michael Beauregard, Janet Huang, MSc, Richard W Heidebrecht, Jr., PhD, Deya Corzo, MD, David Moller, MD, Devyn Smith, PhD, David Peritt, PhD, Rogerio Vivaldi, MD MBA

Blood (2019) 134 (Supplement_1): 2065.

https://doi.org/10.1182/blood-2019-127050

Published: 2019

Journal Articles

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Giada Bianchi, MD, Peter G. Czarnecki, MD, Matthew Ho, PhD, Aldo M. Roccaro, MD PhD, Antonio Sacco, RN, Yawara Kawano, MD PhD, Anil Aktas Samur, PhD, Annamaria Gulla, MD, Tianzeng Chen, Kenneth Wen, Xinchen Wu, Yu-Tzu Tai, PhD, Gulden Camci-Unal, PhD, Irene M. Ghobrial, MD, Ruben D. Carrasco, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 507.

https://doi.org/10.1182/blood-2019-128778

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Ishnoor Sidhu, Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Kristi Lynn Kiick, PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 5010.

https://doi.org/10.1182/blood-2019-130949

Published: 2019

Journal Articles

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Daulath Singh, MD, Patrick Hagen, MD, Nasheed Hossain, MD, Scott E. Smith, MD PhD, Patrick J. Stiff, MD, Stephanie B. Tsai, MD MS

Blood (2019) 134 (Supplement_1): 5726.

https://doi.org/10.1182/blood-2019-129380

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

Fabio Guolo, MD, Paola Minetto, MD, Luana Fianchi, MD, Michela Rondoni, MD, Giulia Daghia, MD, Stefano D'Ardia, MD, Monica Morselli, MD, Crescenza Pasciolla, MD, Francesca Pavesi, MD, Barbara MD Scappini, Francesco Lanza, MD, Marco Gobbi, MD, Livio Pagano, MD, Felicetto Ferrara, MD, Roberto Massimo Lemoli, MD

Blood (2019) 134 (Supplement_1): 1363.

https://doi.org/10.1182/blood-2019-131329

Published: 2019

Journal Articles

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

Tara L Lin, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Daniel H. Ryan, Robert Ryan, Michael Chiarella, Arthur C. Louie, Geoffrey L. Uy, MD

Blood (2018) 132 (Supplement 1): 2706.

https://doi.org/10.1182/blood-2018-99-112557

Published: 2018

Journal Articles

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Qi Wang, PhD, Sarah F. Cook, Scott A. Van Wart, Donald E. Mager, Stefan Faderl, MD

Blood (2018) 132 (Supplement 1): 4037.

https://doi.org/10.1182/blood-2018-99-111918

Published: 2018

Journal Articles

Methotrexate-Loaded Biodegradable Polymeric Micelles for Lymphoma Therapy in Mouse Model

Mengyao Wang, MD, Ying Qu, PhD, Zhiyong Qian, PhD, Ting Niu, MD PhD

Blood (2018) 132 (Supplement 1): 4181.

https://doi.org/10.1182/blood-2018-99-119151

Published: 2018

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Daniel H. Ryan, Geoffrey L. Uy, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Robert K. Stuart, MD, Stephen A. Strickland, MD, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, MD PhD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert Ryan, Michael Chiarella, Arthur C. Louie, Jeffrey E. Lancet, MD

Blood (2018) 132 (Supplement 1): 1425.

https://doi.org/10.1182/blood-2018-99-111514

Published: 2018

Journal Articles

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Gail J. Roboz, MD, Melissa L. Larson, MD, S. Eric Rubenstein, MD, Scott R Solomon, MD, Gary J. Schiller, MD, Qi An, Emaryn Mancino, Michael Chiarella, Arthur C. Louie, Tara L Lin, MD

Blood (2018) 132 (Supplement 1): 1434.

https://doi.org/10.1182/blood-2018-99-111537

Published: 2018

Journal Articles

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Anuraag Kansal, PhD, Odette Reifsnider, Lora Todorova, Anna Coughlan, Kathleen F. Villa

Blood (2018) 132 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2018-99-112252

Published: 2018

Journal Articles

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Jooeun Bae, PhD, Parayath Neha, Mansoor Amiji, Nikhil Munshi, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2018-99-117292

Published: 2018

Journal Articles

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Ivar S Jensen, MBA, Elizabeth Wu, Naomi Sacks, Philip Cyr, MPH, Karen Chung

Blood (2017) 130 (Supplement 1): 5615.

https://doi.org/10.1182/blood.V130.Suppl_1.5615.5615

Published: 2017

Journal Articles

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Geoffrey L. Uy, MD, Jeffrey E. Lancet, MD, Jorge E. Cortes, MD, Laura F. Newell, MD, Tara L. Lin, MD, Ellen K Ritchie, MD, Robert K. Stuart, MD, Stephen A Strickland, Donna Hogge, Scott R Solomon, MD, Richard M. Stone, MD, Dale L. Bixby, Jonathan E. Kolitz, MD, Gary J. Schiller, Matthew J. Wieduwilt, Lynn Shemanski, Michael Chiarella, Arthur C Louie, Bruno C Medeiros, MD

Blood (2017) 130 (Supplement 1): 2647.

https://doi.org/10.1182/blood.V130.Suppl_1.2647.2647

Published: 2017

Journal Articles

CPX-351 Exposure-Response Based on Cumulative Dose of Cytarabine and Daunorubicin in Patients with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Kamalika Banerjee, Qi Wang, Jing Wang, Jackie Gibbons

Blood (2017) 130 (Supplement 1): 1360.

https://doi.org/10.1182/blood.V130.Suppl_1.1360.1360

Published: 2017

NARROW

Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML)

Correcting Rare Blood Disorders Using Coagulation Factors Produced In Vivo By Shielded Living Therapeutics TM Products

The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Liposomal Daunorubicin/Cytarabine As a Bridge to Donor Lymphocyte Infusion or Allogeneic Stem Cell Transplantation for High-Risk Acute Myelogenous Leukemia

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

Population Pharmacokinetic (PK)/Pharmacodynamic (PD) Modeling of Myelosuppression in Patients with Hematologic Malignancies for CPX-351 and Standard-of-Care 7+3 Therapy

Methotrexate-Loaded Biodegradable Polymeric Micelles for Lymphoma Therapy in Mouse Model

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Bcma Heteroclitic Peptide Encapsulated Nanoparticle Enhances Antigen Stimulatory Capacity and Tumor-Specific CD8 + cytotoxic T Lymphocytes Against Multiple Myeloma

Budget Impact Analysis of CPX-351 in the Treatment of Patients with Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC) from a US Payer Perspective

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

CPX-351 Exposure-Response Based on Cumulative Dose of Cytarabine and Daunorubicin in Patients with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only